Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on COVID-19: a novel vaccine approach

NCT ID NCT04299724

Vaccine Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 25, 2026 · Updated 2 times

Summary

This Phase 1 trial tests a new type of COVID-19 vaccine made from artificial antigen presenting cells (aAPC). The vaccine is designed to teach the body's T cells to recognize and attack the SARS-CoV-2 virus. The study includes healthy volunteers and people with mild COVID-19, and will check for side effects and measure immune responses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Covid-19/aAPC vaccine (artificial antigen presenting cells made with lentiviral vector)
What this could lead to
If successful, this vaccine could help prevent or treat severe COVID-19 pneumonia by training the immune system to attack the virus.
What could go wrong
This is an early Phase 1 trial with only 100 participants, so safety and effectiveness are not yet proven. The vaccine uses a lentiviral vector, which may cause unexpected immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

100 people

The number who actually took part.

Started

Jun 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 months to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy and Covid-19-positive volunteers * The interval between the onset of symptoms and randomized is within 7 days in Covid-19 patients. The onset of symptoms is mainly based on fever. If there is no fever, cough or other related symptoms can be used; * White blood cells ≥ 3,500/μl, lymphocytes ≥ 750/μl; * Human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) or tuberculosis (TB) test negative; * Sign the Informed Consent voluntarily; Exclusion Criteria: * Subject with active HCV, HBV or HIV infection. * Subject is albumin-intolerant. * Subject with life expectancy less than 4 weeks. * Subject participated in other investigational vaccine therapies within the past 60 days. * Subject with positive pregnancy test result. * Researchers consider unsuitable.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Treat and prevent COVID-19 infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Treat and prevent COVID-19 infection

Contacts and locations

Locations

  • Shenzhen Geno-immune Medical Institute

    Shenzhen, Guangdong, 518000, China